Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI-0101 in Rheumatoid Arthritis
NCT03241108Phase 2Completed
- Sponsor
- Lightchain Bioscience
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of paridiprubart in rheumatoid arthritis (RA), sponsored by Lightchain Bioscience. Started May 2017; status: completed.
02
Drugs
paridiprubart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03241108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241108.